TRiCBIO combines PDO 2.0 / ALI with tumor, normal-tissue and disease organoids plus multimodal assays for candidate comparison, mechanism studies and safety assessment.
Start with the question your team needs to answer, then select the sample, model, treatment conditions and readouts at the right level of complexity for candidate comparison, mechanism assessment or the next study.
Sample & model identityMechanism-informed designMultimodal analysis
01
Research question
Candidate, sample context and the decision your team needs to make
02
Model & study
Match PDO, PDO 2.0, normal-tissue or disease models with the right dose, controls and co-culture conditions
03
Evidence & decision
Integrate tissue, immune, functional and molecular results for candidate comparison, mechanism and safety decisions
SCIENTIFIC FOUNDATION & FIELD DEVELOPMENT
From ALI tumor-immune organoids to Organoid 2.0
The 2018 Cell study established the ALI tumor–immune organoid foundation. Nature Reviews Cancer featured the approach as “Organoid 2.0” in 2019 and further examined its value for tumor immunity, drug development and mechanism research in a 2024 review. TRiCBIO translates this foundation into PDO 2.0 studies combining model selection, tissue imaging, flow cytometry and functional assays.
Retaining sample-derived immune cells expands what organoids can model
In 2019, Nature Reviews Cancer featured the 2018 Cell ALI tumor–immune organoid study co-first-authored by Xingnan Li under the title “Organoid 2.0.” ALI brings tumor epithelium, tissue architecture and immune cells retained from the source sample into one model, extending organoid research beyond cancer cells alone to the microenvironment.
Anna Dart · 2019 ↗Explore the technology and its applicationsTRiCBIO PDO 2.0 model profiling | Bright-field, H&E, CD3, Pan-CK, Ki67 and immunofluorescence connect tissue identity with immune context.
Immune cells retained from the source sample
Patient-derived immune cells alongside tumor epithelium open the model to tumor–immune interaction studies.
Tumor–stroma relationships
Stromal cells surrounding the tumor epithelium provide tissue context for studying cell interactions.
Sample-specific biology
Genetic and phenotypic features of the source tumor keep the study connected to the biology of the original sample.
Study opportunities
For teams studying how a candidate affects both tumor cells and their immune environment, TRiCBIO combines PDO 2.0 with tissue imaging and immune profiling to investigate activity, cellular interactions and mechanism.
ALI organoids bring sample-associated immune context into immunotherapy research
The 2024 review places the Cell 2018 ALI study within the development of tumor–immune organoid technology and further defines the value of source-tissue stroma, sample-associated immune cells and the tumor T-cell repertoire for checkpoint-blockade, immunotherapy and mechanism studies.
ALI culture brings tumor epithelium, source-tissue stroma and immune cells retained from the sample into one system, providing a multicellular setting for immunotherapy research.
Tumor T-cell repertoire
Preserving the source tumor’s T-cell repertoire supports studies of the sample’s own antitumor immune response.
Checkpoint-blockade studies
Studying responses to checkpoint blockade connects tumor-microenvironment preservation with immunotherapy evaluation.
Study opportunities
For immunotherapy and combination-treatment programs, TRiCBIO pairs PDO 2.0 with immune profiling and functional assays so biopharma and research teams can examine tumor responses, immune changes and candidate mechanisms together.
PDO 2.0 immune studies, antibody distribution imaging, ADC activity and normal organoid safety data support model selection, candidate comparison and organ-risk assessment.
Swipe or use arrow keys to explore more study evidence
PDO 2.0, normal organoids & disease-model programs
Use tumor and normal-tissue organoids plus established IBD inflammation and barrier methods for efficacy, immune and safety studies; tailor ADPKD and BBB programs to the sample, cell source and predefined endpoints.
Tumor PDO & PDO 2.0Normal lung, kidney and gastric models, plus adjacent non-tumor liverIBD inflammation/barrier methods · tailored ADPKD/BBB studies
TRiCBIO combines PDO 2.0 / ALI with tumor, normal-tissue and disease organoids plus multimodal assays for candidate comparison, mechanism studies and safety assessment.
Start with the question your team needs to answer, then select the sample, model, treatment conditions and readouts at the right level of complexity for candidate comparison, mechanism assessment or the next study.
Sample & model identityMechanism-informed designMultimodal analysis
01
Research question
Candidate, sample context and the decision your team needs to make
02
Model & study
Match PDO, PDO 2.0, normal-tissue or disease models with the right dose, controls and co-culture conditions
03
Evidence & decision
Integrate tissue, immune, functional and molecular results for candidate comparison, mechanism and safety decisions
SCIENTIFIC FOUNDATION & FIELD DEVELOPMENT
From ALI tumor-immune organoids to Organoid 2.0
The 2018 Cell study established the ALI tumor–immune organoid foundation. Nature Reviews Cancer featured the approach as “Organoid 2.0” in 2019 and further examined its value for tumor immunity, drug development and mechanism research in a 2024 review. TRiCBIO translates this foundation into PDO 2.0 studies combining model selection, tissue imaging, flow cytometry and functional assays.
Retaining sample-derived immune cells expands what organoids can model
In 2019, Nature Reviews Cancer featured the 2018 Cell ALI tumor–immune organoid study co-first-authored by Xingnan Li under the title “Organoid 2.0.” ALI brings tumor epithelium, tissue architecture and immune cells retained from the source sample into one model, extending organoid research beyond cancer cells alone to the microenvironment.
Anna Dart · 2019 ↗Explore the technology and its applicationsTRiCBIO PDO 2.0 model profiling | Bright-field, H&E, CD3, Pan-CK, Ki67 and immunofluorescence connect tissue identity with immune context.
Immune cells retained from the source sample
Patient-derived immune cells alongside tumor epithelium open the model to tumor–immune interaction studies.
Tumor–stroma relationships
Stromal cells surrounding the tumor epithelium provide tissue context for studying cell interactions.
Sample-specific biology
Genetic and phenotypic features of the source tumor keep the study connected to the biology of the original sample.
Study opportunities
For teams studying how a candidate affects both tumor cells and their immune environment, TRiCBIO combines PDO 2.0 with tissue imaging and immune profiling to investigate activity, cellular interactions and mechanism.
ALI organoids bring sample-associated immune context into immunotherapy research
The 2024 review places the Cell 2018 ALI study within the development of tumor–immune organoid technology and further defines the value of source-tissue stroma, sample-associated immune cells and the tumor T-cell repertoire for checkpoint-blockade, immunotherapy and mechanism studies.
ALI culture brings tumor epithelium, source-tissue stroma and immune cells retained from the sample into one system, providing a multicellular setting for immunotherapy research.
Tumor T-cell repertoire
Preserving the source tumor’s T-cell repertoire supports studies of the sample’s own antitumor immune response.
Checkpoint-blockade studies
Studying responses to checkpoint blockade connects tumor-microenvironment preservation with immunotherapy evaluation.
Study opportunities
For immunotherapy and combination-treatment programs, TRiCBIO pairs PDO 2.0 with immune profiling and functional assays so biopharma and research teams can examine tumor responses, immune changes and candidate mechanisms together.
PDO 2.0 immune studies, antibody distribution imaging, ADC activity and normal organoid safety data support model selection, candidate comparison and organ-risk assessment.
Swipe or use arrow keys to explore more study evidence
PDO 2.0, normal organoids & disease-model programs
Use tumor and normal-tissue organoids plus established IBD inflammation and barrier methods for efficacy, immune and safety studies; tailor ADPKD and BBB programs to the sample, cell source and predefined endpoints.
Tumor PDO & PDO 2.0Normal lung, kidney and gastric models, plus adjacent non-tumor liverIBD inflammation/barrier methods · tailored ADPKD/BBB studies
Plate-based ADC dose response | 2 breast PDO models01Screening & dose response
NSCLC PDO 2.0 | TIL-associated CD4/CD8 readouts02Tumor immune studies and tailored co-culture
HCC tissue–PDO | H&E · CD31 · HEP-103Advanced custom co-development
01Core platform capability
Breast cancer PDO studies | morphology + ADC dose response02Custom ADC distribution study
01Advanced custom functional studies
02Tailored target and mechanism studies
03From organoids to in vivo validation
Complementary glioma studies | GBM lineage · HGM response04Human models & functional research